Overview
IRD market data
Price History
IRD price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IRD. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Top 3 Health Care Stocks That May Rocket Higher In JulyBenzinga · Jul 20, 2026, 10:03 AM
Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026Benzinga · Jul 9, 2026, 11:10 AM
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price TargetBenzinga · Jul 6, 2026, 4:55 PM
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseGlobenewswire Inc · Jul 6, 2026, 11:15 AM
Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal DystrophyBenzinga · Jul 6, 2026, 11:15 AM
Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29Benzinga · Jun 26, 2026, 1:25 PM
Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13Benzinga · Jun 18, 2026, 4:35 PM
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price TargetBenzinga · Jun 17, 2026, 12:10 PM
8-K filing — Opus Genetics, Inc. (IRD)SEC EDGAR · Jun 16, 2026, 8:11 PM
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price TargetBenzinga · Jun 15, 2026, 2:05 PM